| Patient | Elizabeth Tudor |
|---|---|
| Date of birth | 1533-09-17 |
| Identifiers | MRN HR-RE003-SYN-TD; SSN (made up) 000-03-5529 |
| Document date | 1603-03-16 |
| Author | Philippa Ashcombe-Nwosu, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Seven-week depression treatment review. [S]
Ms. Tudor returns seven weeks after starting sertraline, now six weeks at 50 mg. She has had six sessions of interpersonal psychotherapy and has been able, for the first time, to talk about the friend she lost two years ago and her part in the breach between them. Her mood is lighter on most days; she has resumed audiences on most mornings, played music twice, and seen two old friends. She sleeps about five and a half hours. Her new partial denture is to be fitted next week, and she eats more, though still slowly. She has had no side effects, no falls, and no thoughts of death or self-harm. [S]
| Element | Detail |
|---|---|
| Medication | Sertraline 50 mg for six weeks; no side effects |
| Psychotherapy | Six IPT sessions, focused on grief |
| Sleep | About five and a half hours; Insomnia Severity Index 11 |
| Function | Audiences most mornings; music and friends again |
| Safety | No suicidal thoughts |
| PHQ-9 | 8, down from 17 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Appetite better; weight 53.4 kg |
| Gastrointestinal | Negative | No nausea, diarrhea, or bleeding |
| Musculoskeletal | Negative | No falls; shoulder ache settled |
| Psychiatric | Positive | Mood lighter but not yet back to her usual; no suicidal thoughts, elevated mood, or agitation |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Diphenhydramine 25 mg oral capsule (over the counter), one or two capsules at bedtime for sleep | One or two capsules at bedtime | Oral route | 1602-12-01 to 1603-01-12 | completed | S |
| Sertraline 25 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1603-01-26 to 1603-02-02 | completed | S |
| Sertraline 50 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1603-02-02 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain or fever, no more than 3 g a day | Two tablets every 6 hours as needed; no more than six tablets a day | Oral route | 1603-02-02 to 1603-02-23 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1603-03-16 | Body height | 163 | cm | S |
| 1603-03-16 | Body weight | 53.4 | kg | S |
| 1603-03-16 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 1603-03-16 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1603-03-16 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1603-03-16 | Heart rate | 70 | /min | S |
| 1603-03-16 | Respiratory rate | 14 | /min | S |
| 1603-03-16 | Body temperature | 36.5 | Cel | S |
| 1603-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1603-03-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 1603-03-16 | Geriatric depression scale (GDS) short version total | 4 | {score} | S |
Vital signs recorded on 1603-03-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin but better nourished; animated |
| Mental status | Warm and engaged; normal pace of speech; mood "much lighter"; affect reactive; no suicidal ideation; no psychotic features |
| Cardiovascular | Blood pressure 124/72 mmHg seated, no orthostatic drop; pulse 70 |
| Musculoskeletal | Timed Up and Go 10 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Low mood, sleeplessness (about four hours a night), poor appetite, and unintended loss of 3.5 kg (6 percent) over three months, after bereavements and in a demanding public role; under evaluation for depression and medical causes | resolved | confirmed | R45.89 | S — Synthetic presenting concern at the index visit, echoing the documented low spirits and poor appetite of her last months; superseded by the depression diagnosis at the second visit. |
| Major depressive disorder, single episode, moderate (PHQ-9 17 and GDS-15 10 at intake), in an older woman after bereavements; medical causes excluded | active | confirmed | F32.1 | S — Synthetic modern diagnosis. Her deep melancholy, sleeplessness, and refusal of food in her last months are documented (D); calling them major depression is a modern reading, and no diagnosis was made in her lifetime. |
| Chronic insomnia comorbid with depression: sleep-maintenance and early-morning waking for three months, Insomnia Severity Index 19 | active | confirmed | G47.00 | S — Synthetic diagnosis echoing the documented sleeplessness of her last months. |
| Partial loss of teeth with an ill-fitting upper partial denture and painful chewing, contributing to poor intake | active | confirmed | K08.409 | S — Synthetic dental finding echoing the documented description of her teeth; no cause is asserted. |
| One fall in the past year (a stumble boarding a boat, with bruised shins) and low body weight; fall risk | active | confirmed | Z91.81 | S — Synthetic fall-risk problem anchored to her documented stumble and fall in December 1602. |
| Acute viral pharyngitis with a low-grade fever, cough, and runny nose; no features of streptococcal infection or a peritonsillar abscess; resolved | resolved | confirmed | J02.9 | S — Synthetic intercurrent illness at an unscheduled visit; it echoes the documented cold of January 1603 (CLM-0012) and asserts no cause for the inflammation and throat symptoms reported later. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 8, down from 17 (53 percent): response; remission is PHQ-9 below 5 |
| Survey | GDS-15 | Baseline and to monitor response in adults 65 or older (monthly here) | Completed today | 4, below the cutoff of 5 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; PHQ-9 item 9 scored 0 |
| Laboratory | Sodium on an SSRI | After starting, after dose increases, and with symptoms | Not indicated | 136 mmol/L four weeks after starting; no dose change and no confusion, nausea, or unsteadiness |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no side effects |
| Referral | Interpersonal psychotherapy | Weekly | Completed today | Six sessions; grief focus |
| Examination | Weight and nutrition | Every visit while weight is below her usual | Completed today | 53.4 kg, up 1.0 kg since the diagnosis visit; usual weight 55.9 kg |
| Examination | Fall risk on an SSRI: orthostatic blood pressure, gait, and falls since the last visit | At baseline, after starting an SSRI, and with dose changes | Completed today | No falls; no orthostatic drop; Timed Up and Go 10 seconds |
| Imaging | DXA of the hip and spine | Once for women 65 or older; ordered at the wellness visit | Due | Booked for next week; no result yet |
| Self-management | Sleep (CBT-I), activity, and social contact | Every visit during active treatment | Completed today | Insomnia Severity Index 11; audiences, music, and friends resumed |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |
Goal progress:
Guideline basis: APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); Osteoporosis to Prevent Fractures: Screening (2025)
Follow-up: Depression review in four weeks, at about twelve weeks of treatment. [S]